FINASTERIDE by Cipla is 5α-reductase, an intracellular enzyme that converts the androgen testosterone into dht. Approved for male pattern hair loss (androgenetic alopecia) in men only. First approved in 2014.
Drug data last refreshed 18h ago
5α-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and developmental stages. In humans, Type I 5α-reductase is…
Worked on FINASTERIDE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy